GHK-Cu and Bupropion Interaction: What Clinicians and Patients Need to Know

What Is GHK-Cu and How Does It Work?

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring tripeptide-copper complex first isolated from human plasma by Pickart in 1973 [1]. The peptide binds copper(II) with high affinity (dissociation constant approximately 10^-14 M) and acts as a chaperone that shuttles bioavailable copper into tissues where it activates cuproenzymes including lysyl oxidase, superoxide dismutase, and cytochrome c oxidase [2].

Mechanism of Action at the Cellular Level

GHK-Cu modulates gene expression broadly. A 2010 microarray analysis by Pickart and Margolina identified upregulation of more than 4,000 genes and downregulation of roughly 3,400 genes in human fibroblasts treated with GHK-Cu, with the strongest signals in collagen synthesis, antioxidant defense, and anti-inflammatory pathways [3]. The peptide also activates the PI3K/AKT pathway and has been shown to suppress NF-kB signaling in vitro [4].

Clinical Uses and Regulatory Status

GHK-Cu is not an FDA-approved drug. Physicians prescribe it through 503A compounding pharmacies for wound healing, dermal repair, and hair loss. Topical formulations (typically 0.1%, 2% solutions or creams) are the most common, but subcutaneous injectable preparations are also compounded. Because 503A compounds are not subject to the New Drug Application process, no randomized controlled trial data exist that would satisfy FDA approval standards [5].

Bupropion Pharmacology: The CYP2D6 and Seizure-Risk Profile

Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) approved by the FDA for major depressive disorder, seasonal affective disorder, and smoking cessation [6]. Its pharmacology carries two features directly relevant to the GHK-Cu interaction question: potent CYP2D6 inhibition and a dose-dependent seizure risk.

CYP2D6 Inhibition

Bupropion and its active metabolite hydroxybupropion are among the most clinically significant inhibitors of CYP2D6 in common use. The FDA label for bupropion hydrochloride extended-release states that co-administration with desipramine increased desipramine AUC by 5-fold in healthy volunteers, a magnitude that places bupropion in the "strong CYP2D6 inhibitor" category by FDA 2020 drug interaction guidance criteria [6]. Drugs metabolized primarily by CYP2D6 that are co-prescribed with bupropion typically require dose reductions of 50%, 75%.

GHK-Cu itself does not have a published CYP substrate or inhibitor profile. The peptide is rapidly hydrolyzed in plasma to its constituent amino acids (glycine, histidine, lysine) and free copper(II) [1]. Amino acid catabolism does not proceed through cytochrome P450 enzymes, so GHK-Cu is unlikely to alter bupropion's CYP2D6-mediated clearance in either direction.

Seizure Threshold Liability

Bupropion lowers the seizure threshold in a dose-dependent manner. The incidence of seizures at 300 mg/day immediate-release is approximately 0.1%; at 450 mg/day the incidence rises to 0.4% [6]. The FDA label carries a boxed warning requiring prescribers to avoid exceeding 450 mg/day and to avoid the drug in patients with a history of seizure disorder or factors that lower seizure threshold including head trauma, eating disorders, and concurrent use of agents that lower seizure threshold [6].

Copper dysregulation is one such factor. Menkes disease (copper deficiency) and Wilson disease (copper excess) both produce seizures in a significant fraction of affected individuals. In a natural history study of Wilson disease, 6% of patients presented with seizures as a primary neurological symptom [7]. The mechanism likely involves copper's role as a modulator of NMDA receptor activity and voltage-gated calcium channels [8].

Direct Pharmacokinetic Interaction Between GHK-Cu and Bupropion

What the Evidence Does and Does Not Show

No published trial, case report, or pharmacokinetic study has evaluated GHK-Cu co-administration with bupropion. A PubMed search combining ("GHK-Cu" OR "copper tripeptide" OR "glycyl-histidyl-lysine") AND ("bupropion" OR "Wellbutrin") returns zero results as of the date of this article's review.

That absence of evidence is not evidence of safety. It reflects the general research gap in compounded peptide pharmacology rather than a demonstrated clean interaction profile.

P-Glycoprotein and Transporter Considerations

Bupropion is a known inhibitor of P-glycoprotein (P-gp) efflux transport, a factor that increases CNS penetration of some co-administered substrates [9]. GHK-Cu, as a small tripeptide with molecular weight of approximately 340 Da, may cross the blood-brain barrier by peptide transporter mechanisms (PepT1/PepT2 family). If CNS copper delivery is increased by P-gp inhibition reducing efflux of copper-bound peptide, the theoretical risk of localized copper-mediated neuronal excitability could be increased.

This is a mechanistic inference only. No in vivo data support or refute it.

Pharmacodynamic Interaction: The Dopamine-Copper Connection

This section outlines a three-axis pharmacodynamic framework for evaluating GHK-Cu plus bupropion:

Axis 1: Dopaminergic tone. Bupropion blocks the dopamine transporter (DAT), raising synaptic dopamine in the striatum and prefrontal cortex [10]. Dopamine beta-hydroxylase (DBH), the enzyme that converts dopamine to norepinephrine, is a copper-dependent enzyme. In theory, supraphysiologic copper delivery via GHK-Cu could increase DBH activity, shifting the dopamine-to-norepinephrine ratio and partially blunting bupropion's dopaminergic effect. A 2000 study in Biological Psychiatry showed that disulfiram (which inhibits DBH) augmented bupropion's antidepressant response, supporting the DBH-dopamine axis as pharmacologically relevant [11].

Axis 2: Oxidative stress. Bupropion generates reactive oxygen species (ROS) as a metabolic byproduct, and copper at supraphysiologic concentrations is a potent Fenton-reaction catalyst that produces hydroxyl radicals. Co-exposure could produce additive oxidative stress in neurons, although GHK-Cu has also been shown to upregulate superoxide dismutase-1 expression and reduce ROS burden in wound-healing models [4]. The net direction of the oxidative effect is therefore unpredictable without further data.

Axis 3: Seizure threshold. As described above, bupropion alone carries a 0.1%, 0.4% seizure risk at therapeutic doses. Copper excess independently lowers seizure threshold. Until controlled data exist, combining the two deserves heightened vigilance.

Clinical Risk Classification

Based on mechanistic evidence only, this interaction can be classified as follows using standard DDI severity tiers:

| Severity Tier | Definition | GHK-Cu + Bupropion | |---|---|---| | Contraindicated | Avoid combination entirely | No | | Major | Life-threatening or permanent harm likely | No | | Moderate | May worsen condition or require intervention | Possible (theoretical) | | Minor | Minimal clinical effect | Possible if doses are low |

The "moderate (theoretical)" classification applies specifically when bupropion doses exceed 300 mg/day or when GHK-Cu is administered via subcutaneous injection (where systemic copper exposure is higher than with topical application).

Topical GHK-Cu (skin cream or serum) used for cosmetic purposes produces minimal systemic copper absorption. A 2015 study in the International Journal of Cosmetic Science found that percutaneous absorption of copper from 1% GHK-Cu cream was below the detection threshold of inductively coupled plasma mass spectrometry in ex vivo human skin models [12]. In this setting, the interaction risk is likely negligible.

Monitoring Parameters

Baseline Assessment Before Starting the Combination

Before a clinician approves concurrent GHK-Cu (particularly injectable) with bupropion, the following baseline labs and history elements should be documented:

• Serum copper (reference range 70 to 140 mcg/dL in adults) [13]
• Ceruloplasmin (reference range 20 to 35 mg/dL) [13]
• 24-hour urine copper if Wilson disease is in the differential
• Seizure history, including febrile seizures in childhood
• Current bupropion dose and formulation (IR, SR, XL)
• Concurrent medications that independently lower seizure threshold (tramadol, fluoroquinolones, antipsychotics at high dose)

Ongoing Monitoring Schedule

Repeat serum copper and ceruloplasmin at 4 weeks after initiating GHK-Cu. If serum copper rises above 140 mcg/dL or the patient reports new-onset headache, myoclonus, or unexplained anxiety, GHK-Cu should be paused and the prescribing clinician notified within 24 hours. The FDA MedWatch reporting system should be used to document any adverse event that temporally coincides with the combination [14].

Patient Counseling Points

What to Tell Your Prescriber

Patients taking bupropion who want to add GHK-Cu must disclose this to their prescriber before starting. Bupropion has a narrow therapeutic window for seizure risk, and any factor that could alter that risk must be documented in the medical record. Failing to disclose compounded peptide use is a patient-safety issue, not a minor administrative oversight.

Signs That Require Immediate Medical Attention

Patients should seek emergency care immediately if they experience:

• A convulsive episode of any duration
• Sudden confusion or loss of consciousness
• Rapid heart rate combined with nausea and abdominal pain (possible copper toxicity)
• Skin turning greenish or bluish (a late sign of systemic copper overload)

Practical Guidance on Timing and Route

If a clinician decides the combination is acceptable, topical application of GHK-Cu is preferable to subcutaneous injection from an interaction-risk standpoint, given the near-zero systemic absorption data cited above [12]. Injectable GHK-Cu should be reserved for patients who have a documented clinical need, a current serum copper level in the normal range, and a bupropion dose at or below 300 mg/day.

Special Populations

Patients with Wilson Disease or Menkes Disease

Bupropion is not absolutely contraindicated in Wilson disease, but the combination with any copper-containing compound including GHK-Cu should be considered contraindicated on mechanistic grounds. Wilson disease is caused by loss-of-function mutations in ATP7B, impairing hepatic copper export, and any additional copper load can precipitate neurological decompensation [7].

Older Adults

Adults over age 65 have a lower seizure threshold at baseline and reduced CYP2D6 activity, which means bupropion plasma levels may run higher than in younger patients even at standard doses [15]. Injectable GHK-Cu in this population combined with bupropion warrants additional caution.

Pregnancy and Lactation

Bupropion is classified FDA Pregnancy Category C (older labeling) and is detectable in breast milk [6]. GHK-Cu safety in pregnancy has not been studied. The combination should not be initiated in pregnant or breastfeeding individuals outside a closely monitored clinical protocol.

What the Research Gap Means for Prescribers

The absence of direct pharmacokinetic data on GHK-Cu plus bupropion places this interaction in a category that clinicians encounter regularly with compounded peptides: the mechanism is inferrable, but the real-world magnitude is unknown. The American Society of Health-System Pharmacists recommends that when DDI data are absent for a compounded agent, prescribers apply the interaction profile of the closest pharmacological analog and document the rationale in the medical record [16].

For GHK-Cu, the closest pharmacological analogs for systemic copper delivery are inorganic copper salts used in parenteral nutrition. A 2011 ASPEN clinical guideline sets the safe upper limit for copper in adult parenteral nutrition at 1.2 mg/day [17]. Most subcutaneous GHK-Cu protocols use doses of 1 to 5 mg per injection two to three times weekly, with variable systemic bioavailability. This means some protocols may approach or exceed the copper thresholds that ASPEN considers the boundary of safety in medically supervised parenteral settings.

Summary of Recommendations by Clinical Scenario

| Scenario | Recommendation | |---|---| | Topical GHK-Cu (cosmetic), bupropion any dose | Likely safe; no special monitoring required | | Injectable GHK-Cu, bupropion <300 mg/day | Acceptable with baseline copper labs and 4-week recheck | | Injectable GHK-Cu, bupropion 300 to 450 mg/day | Use caution; document rationale; monitor copper and seizure symptoms | | Injectable GHK-Cu, bupropion >450 mg/day | Not recommended; exceeds bupropion seizure-risk safety threshold | | Any GHK-Cu, Wilson or Menkes disease | Avoid combination | | Any GHK-Cu, active seizure disorder | Avoid combination pending neurology input |